- Home
- UBX
as 07-26-2024 4:00pm EST
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 24.7M | IPO Year: | 2018 |
| Target Price: | $9.00 | AVG Volume (30 days): | 39.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.22 - $2.99 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Unity Biotechnology Inc. (UBX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sullivan Lynne Marie | UBX | CFO & Head of Corp. Dev. | Jun 25 '24 | Sell | $1.40 | 324 | $453.60 | 32,685 | SEC Form 4 |
| Ghosh Anirvan | UBX | Chief Executive Officer | Jun 25 '24 | Sell | $1.40 | 1,214 | $1,699.60 | 76,929 | SEC Form 4 |
| Nguyen Alexander Hieu | UBX | Chief Legal Officer | Jun 25 '24 | Sell | $1.40 | 78 | $109.20 | 25,026 | SEC Form 4 |
| Ghosh Anirvan | UBX | Chief Executive Officer | May 2 '24 | Sell | $1.55 | 603 | $934.65 | 78,143 | SEC Form 4 |
| Ghosh Anirvan | UBX | Chief Executive Officer | Feb 2 '24 | Sell | $1.71 | 680 | $1,162.80 | 78,746 | SEC Form 4 |
| Ghosh Anirvan | UBX | Chief Executive Officer | Jan 30 '24 | Sell | $1.71 | 1,183 | $2,022.93 | 79,426 | SEC Form 4 |
| Ghosh Anirvan | UBX | Chief Executive Officer | Nov 2 '23 | Sell | $1.83 | 589 | $1,077.87 | 80,609 | SEC Form 4 |
| Ghosh Anirvan | UBX | Chief Executive Officer | Oct 30 '23 | Sell | $1.90 | 1,024 | $1,945.60 | 81,198 | SEC Form 4 |
Latest Unity Biotechnology Inc. News
UBX Breaking Stock News: Dive into UBX Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
UNITY Biotechnology Reports Granting of New Employment Inducement Award
GlobeNewswire
5 days ago
UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer
Simply Wall St.
24 days ago
Is Unity Biotechnology (NASDAQ:UBX) In A Good Position To Invest In Growth?
Zacks
2 months ago
All You Need to Know About UNITY Biotechnology (UBX) Rating Upgrade to Buy
GlobeNewswire
2 months ago
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates
GlobeNewswire
3 months ago
UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting
MT Newswires
3 months ago
Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment
GlobeNewswire
3 months ago
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME
Compare UBX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "UBX Unity Biotechnology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.